Studies tumor rupture during robotic surgery to remove part of a kidney
Looks at what happens when a kidney tumor breaks during robotic partial nephrectomy in adults.
Plain-language title generated from the registry record
Registry title: Tumor Rupture During Robotic Partial Nephrectomy
Key facts
- Where
- Verona, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07065825, who can take part
Where in Italy
- AOUI VeronaVerona, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Ospedaliera Universitaria Integrata Verona
- Trial code
- NCT07065825
- Record updated
- 15 July 2025
- Original description
The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors. Tumor rupture-an unintended break of the tumor capsule during surgery-occurs in about 10-15% of cases but is poorly studied. This event may increase the risk of cancer recurrence or spread, but its true impact is still unclear.Read full original descriptionShow less
A Retro-Prospective Observational Study on Causes, Characteristics, Intraoperative Management and Impact on Prognosis
The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors. Tumor rupture-an unintended break of the tumor capsule during surgery-occurs in about 10-15% of cases but is poorly studied. This event may increase the risk of cancer recurrence or spread, but its true impact is still unclear.
The study includes adult patients who experienced a tumor rupture during RAPN. Researchers will collect data on patient and tumor characteristics, surgical techniques, how the rupture occurred and was managed, and long-term outcomes. Follow-up visits will monitor for recurrence, metastases, and survival for up to five years. No experimental treatments or extra procedures are involved; only standard care is followed.
By analyzing at least 100 cases from various hospitals, the study hopes to clarify whether tumor rupture affects prognosis and to identify risk factors and best practices for managing it. This could help improve patient safety, surgical strategies, and future clinical guidelines. All data are handled confidentially, and participation is voluntary.
Inclusion: Patients who experienced tumor rupture during RAPN (referred to an unintended breach of the tumor capsule with or without spillage of malignant tissue during tumor resection); Patients who provide informed consent to participate; Patients from 18 to 80 years of age.
Exclusion: Patients undergoing radical nephrectomy or other nephron-sparing procedures; Patients undergoing partial nephrectomy with other approaches (open, pure laparoscopic); Patients with multiple ipsilateral tumors; Patients diagnosed with genetic abnormalities that increase the likelihood of developing renal cell carcinoma; Patients who deny consent.